WELCOME TO SYNOSIA THERAPEUTICS
Synosia Therapeutics develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. We use cutting-edge technologies and creative clinical study designs to de-risk our compounds before moving into larger, more extensive Phase II and Phase III programmes. We currently have six clinical-stage compounds in our pipeline for neurological and psychiatric diseases with high unmet medical need, including Parkinson’s and Alzheimer’s disease. For doctors, this means potential new treatment options for debilitating neurological conditions. For patients, it could mean vast improvements in quality of life.